A scare has broken out over the breast cancer drug tamoxifen, with women being advised that the drug may, in certain circumstances, be responsible for an increased risk of secondary tumours. Medical charities have moved to play down the concerns but, according to the guardian website, US research has indicated that those using tamoxifen for a period of five years were more vulnerable to developing more aggressive tumours, as opposed to those which require oestrogen, which tamoxifen targets.
Read More